Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis-resistant" BALB/c mouse lungs.
The individual susceptibility to pulmonary fibrosis (PF) remains a mystery, suggesting a role for genetic predisposition. The pathogenesis of PF involves a multitude of factors mediating crosstalk between various tissue components. Some factors, such as transforming growth factor beta, are recognized as key elements in the process, whereas the role of others, such as connective tissue growth factor (CTGF), is unclear. We investigated if Balb/c mice, known to be fibrosis resistant partly due to lack of CTGF induction upon stimulation with bleomycin, can be transformed into fibrosis-sensitive individuals by generation of a CTGF-rich environment using transient overexpression of CTGF by adenoviral gene transfer (AdCTGF). We show that AdCTGF is not sufficient to cause fibrosis, and that bleomycin challenge results in inflammation, but not fibrosis, in Balb/c mouse lungs. This inflammation is accompanied by lower levels of CTGF and tissue inhibitor of metalloproteinase-1 gene expression compared with fibrosis-prone C57BL/6 mice. However, concomitant administration of AdCTGF and bleomycin leads to a persistent upregulation of tissue inhibitor of metalloproteinase-1 gene and a significant fibrotic response in Balb/c similar to that in C57BL/6 mice. We propose that CTGF is an important mediator in the pathogenesis of PF in that it provides a local microenvironment in the lung that causes individual susceptibility. CTGF should be considered as a novel drug target and as a potential marker for identifying individuals at risk.
Bonniaud
Philippe
P
Departments of Medicine, Pathology and Molecular Medicine, Center for Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada.
Martin
Gail
G
Margetts
Peter J
PJ
Ask
Kjetil
K
Robertson
Jennifer
J
Gauldie
Jack
J
Kolb
Martin
M
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D001761:Bleomycin / Q000494:pharmacology; D018893:Bronchoalveolar Lavage; D055513:Connective Tissue Growth Factor; D017931:DNA Primers / Q000494:pharmacology; D005260:Female; D005355:Fibrosis; D018014:Gene Transfer Techniques; D020022:Genetic Predisposition to Disease; D006909:Hydroxyproline / Q000737:chemistry; D017874:Immediate-Early Proteins / Q000502:physiology*; D007249:Inflammation; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology*; D008168:Lung / Q000166:cytology* / Q000378:metabolism; D045726:Metalloproteases / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism; D012306:Risk; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000378:metabolism; D053773:Transforming Growth Factor beta1; D015854:Up-Regulation
C526318:CCN2 protein, mouse; D017931:DNA Primers; D017874:Immediate-Early Proteins; D036341:Intercellular Signaling Peptides and Proteins; D012333:RNA, Messenger; C508961:Tgfb1 protein, mouse; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D001761:Bleomycin; D055513:Connective Tissue Growth Factor; D045726:Metalloproteases; D006909:Hydroxyproline